Equities Analysts Set Expectations for Protagonist Therapeutics, Inc.’s FY2028 Earnings (NASDAQ:PTGX)

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) – Stock analysts at Capital One Financial issued their FY2028 earnings per share estimates for shares of Protagonist Therapeutics in a report released on Wednesday, January 31st. Capital One Financial analyst T. Chiang anticipates that the company will earn ($0.95) per share for the year. Capital One Financial […]

Leave a Reply

Your email address will not be published.

Previous post Piper Sandler Trims Aptose Biosciences (NASDAQ:APTO) Target Price to $5.00
Next post Brokerages Set Canadian Natural Resources Limited (NYSE:CNQ) Price Target at $94.00